The $30M seems like a minimum amount as they have $5M to PGNX upon approval and this only leaves ~$2.5M per month for 10 months. Fine’s $90-100M estimate seems more a best case and definitely more than the minimum to get to revenue. My thoughts are somewhere in-between would be ideal.....maybe $40-50M. If they can get a big upfront payment of $100M that is great, but will likely be tied to lower royalty than say if they get $30-50M. I would prefer them not to walk on a thin line as they have a lot of trials to complete and I wouldn’t want financing to slow them down.
I’m sure they have a good idea of what the expected burn rate will be, but they have been a little too optimistic at times.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.